Cargando…

Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia

Positive and Negative Syndrome Scale (PANSS) total score is the standard primary efficacy measure in acute treatment studies of schizophrenia. However, PANSS factors that have been derived from factor analytic approaches over the past several decades have uncertain clinical and regulatory status as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hopkins, Seth C, Ogirala, Ajay, Loebel, Antony, Koblan, Kenneth S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Regular Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890480/ https://www.ncbi.nlm.nih.gov/pubmed/28981857 http://dx.doi.org/10.1093/schbul/sbx101

Ejemplares similares

T109. CLUSTERING OF SCHIZOPHRENIA PATIENT SUBTYPES BY SPECIFIC SYMPTOM DIMENSIONS USING AN UNCORRELATED PANSS SCORE MATRIX (UPSM)
por: Hopkins, Seth, et al.
Publicado: (2018)

Patterns of schizophrenia symptoms: hidden structure in the PANSS questionnaire
por: Lefort-Besnard, Jérémy, et al.
Publicado: (2018)

Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia
por: Leucht, Stefan, et al.
Publicado: (2019)

Depressive Symptoms and PANSS Symptom Dimensions in Patients With Predominant Negative Symptom Schizophrenia: A Network Analysis
por: Demyttenaere, Koen, et al.
Publicado: (2022)

Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study
por: Fountoulakis, Konstantinos N, et al.
Publicado: (2019)

The Correlation of Positive and Negative Symptoms (PANSS Scores) in Patients with Schizophrenia According to Gender
por: Sulejmanpasic, Gorana, et al.
Publicado: (2023)

Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS
por: Hopkins, Seth C., et al.
Publicado: (2021)

Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis
por: Hieronymus, Fredrik, et al.
Publicado: (2021)

Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D(2)-Based Pharmacological Class Effect Query Defined by FAERS
por: Hopkins, Seth C., et al.
Publicado: (2022)

Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study
por: Correll, Christoph U., et al.
Publicado: (2021)

Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression
por: Loebel, Antony, et al.
Publicado: (2015)

M210. GRIN2B METHYLATION IS RELATED TO PANSS EXCITED COMPONENT (PANSS-EC) IN SCHIZOPHRENIA
por: Fachim, Helene, et al.
Publicado: (2020)

Assessment and correlates of autistic symptoms in Schizophrenia Spectrum Disorders measured with the PANSS Autism Severity Score: A systematic review
por: Nibbio, Gabriele, et al.
Publicado: (2022)

Schizophrenia, Depressive Symptoms, and Antipsychotic Drug Treatment
por: Reynolds, Gavin P, et al.
Publicado: (2021)

S46. THE VALIDITY AND SENSITIVITY OF PANSS-6 IN TREATMENT-RESISTANT SCHIZOPHRENIA
por: Ostergaard, Soren Dinesen, et al.
Publicado: (2018)

S48. INTER-RATER RELIABILITY OF PANSS-6 SCHIZOPHRENIA SEVERITY RATINGS OBTAINED USING THE SIMPLIFIED NEGATIVE AND POSITIVE SYMPTOMS INTERVIEW (SNAPSI)
por: Kølbæk, Pernille, et al.
Publicado: (2018)

Negative Symptoms in Early-Onset Psychosis and Their Association With Antipsychotic Treatment Failure
por: Downs, Johnny, et al.
Publicado: (2019)

Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US
por: O’Day, Ken, et al.
Publicado: (2013)

S71. CLINICAL, BEHAVIOURAL AND NEURAL VALIDATION OF THE POSITIVE AND NEGATIVE SYMPTOM SCALE (PANSS) AMOTIVATION FACTOR
por: Kaliuzhna, Mariia, et al.
Publicado: (2020)

S244. RELIABILITY OF CORE SCHIZOPHRENIA SYMPTOMS RATINGS USING THE SIX-ITEM POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS-6) PERFORMED BY MEDICAL STUDENTS
por: Hansen, Johanna, et al.
Publicado: (2020)

What Is the Minimum Clinically Important Change in Negative Symptoms of Schizophrenia? PANSS Based Post-hoc Analyses of a Phase III Clinical Trial
por: Czobor, Pál, et al.
Publicado: (2022)

Outpatient Antipsychotic Treatment and Inpatient Costs of Schizophrenia
por: Marcus, Steven C., et al.
Publicado: (2008)

M208. MEASURES OF COGNITION AND SOCIAL FUNCTIONING IN SCHIZOPHRENIA PATIENTS RECEIVING SEP-363856
por: Milanovic, Snezana, et al.
Publicado: (2020)

A Network Approach to Trauma, Dissociative Symptoms, and Psychosis Symptoms in Schizophrenia Spectrum Disorders
por: Schlesselmann, Ante J, et al.
Publicado: (2022)

Study on risk factors of extrapyramidal symptoms induced by antipsychotics and its correlation with symptoms of schizophrenia
por: Weng, Jiajun, et al.
Publicado: (2019)

Factor analysis of the relationship between PANSS score and family burden of patients with schizophrenia
por: Huang, Jiang, et al.
Publicado: (2021)

S49. EFFICACY OF HIGH-FREQUENCY REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION ON PANSS FACTORS IN SCHIZOPHRENIA WITH PREDOMINANT NEGATIVE SYMPTOMS – RESULTS FROM AN EXPLORATORY RE-ANALYSIS
por: Hansbauer, Maximilian, et al.
Publicado: (2018)

T111. PANSS NEGATIVE SYMPTOM DIMENSIONS ACROSS GEOGRAPHICAL REGIONS: IMPLICATIONS FOR SOCIAL, LINGUISTIC AND CULTURAL CONSISTENCY
por: Khan, Anzalee, et al.
Publicado: (2018)

Primary Nonadherence to Antipsychotic Treatment Among Persons with Schizophrenia
por: Lieslehto, Johannes, et al.
Publicado: (2022)

Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation
por: Loebel, Antony, et al.
Publicado: (2015)

Attention to Irrelevant Cues Is Related to Positive Symptoms in Schizophrenia
por: Morris, Richard, et al.
Publicado: (2013)

Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
por: Davidson, Michael, et al.
Publicado: (2022)

Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults
por: Hopkins, Seth C., et al.
Publicado: (2015)

Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults
por: Koblan, Kenneth S, et al.
Publicado: (2015)

Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5‐HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders
por: Hopkins, Seth C., et al.
Publicado: (2021)

Adding antidepressants to antipsychotics for treatment of subsyndromal depressive symptoms in schizophrenia: Impact on positive and negative symptoms
por: Vahia, Ipsit V., et al.
Publicado: (2013)

An Assessment of Five (PANSS, SAPS, SANS, NSA-16, CGI-SCH) commonly used Symptoms Rating Scales in Schizophrenia and Comparison to Newer Scales (CAINS, BNSS)
por: Kumari, Suneeta, et al.
Publicado: (2017)

Item Response Theory to Quantify Longitudinal Placebo and Paliperidone Effects on PANSS Scores in Schizophrenia
por: Krekels, EHJ, et al.
Publicado: (2017)

The Interaction of Polymorphisms of IL10 and DBH Was Associated with General Symptoms of PANSS with TD in Chinese Han Schizophrenic Patients
por: Sun, Hongqiang, et al.
Publicado: (2013)

Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics
por: Lin, Ching-Hua, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6kqe0lqkshk50mevdu2ecuih7j